BIA Separations launches purification technology for AAV production

By Vassia Barba contact

- Last updated on GMT

(Image: Getty/Design Cells)
(Image: Getty/Design Cells)

Related tags: BIA Separations, Process development, adeno-associated virus, Viral vector

BIA Separations introduces technology able to remove host-cell DNA and proteins from AAV products, aiming to accelerate clinical development of gene therapies.

BIA Separations has launched Cornerstone, a set of services designed to facilitate adeno-associated virus (AAV) production.

The first service to be provided through the Cornerstone program is a purification technology called CIMasphere, which enables the removal of impurities such as host-cell protein, host-cell DNA and their complexes prior to the manufacturing processes, in order to deliver ‘ultra-pure’ AAV products.

Pete Gagnon, BIA Separations’ CEO, said in a statement that the company plans to introduce additional tools over the coming months, as well as to include other viral vectors, exosomes, mRNA, and DNA plasmids in the Cornerstone program.

The newly-launched service is expected to respond to an ‘urgent’ need in the biopharmaceutical industry for turn-key gene therapy production processes, according to Ingo Nagler, the company’s business development officer.

Earlier this year, the company entered an agreement ​with AveXis for the commercial purification process of SMA gene therapy drug Zolgensma (onasemnogene abeparvovec-xioi), as well as further gene therapy candidates in the latter’s pipeline.

Breaking down tightly packed chromatins

According to the company, host-cell DNA and proteins are among the most problematic contaminants to remove during AAV manufacture, since they appear as tightly packed complexes in the form of chromatin.

“Commercially available nucleases for purification processes struggle to break down chromatin, as it is protected by host-cell DNA’s strong histone associations,”​ the company stated.

In contrast to that, BIA Separation’s CIMasphere technology takes advantage of these strong associations and uses them to selectively remove the contaminants that cause ‘the most problems’.

Shifting to bioprocessing services

Commenting on the launch, Ingo Nagler said that it reflects a transition for BIA from a product supplier to a service provider for gene therapies development.

In late 2018, the company expanded its facilities in Ajdovščina, Slovenia, with the addition ​of an upstream laboratory, allowing the production of viral vectors, phages, and exosomes, as well as better management of the transition between upstream and downstream processing.

The addition of the laboratory followed a collaboration agreement ​with Nuvonis Technologies, under which BIA gained access to the latter’s cell bank.

Related news

Show more

Related products

show more

dPCR Case Study

dPCR Case Study

CellCarta | 08-Aug-2022 | Case Study

Streamline your adoptive cell therapy program with digital PCR. Our team has a unique expertise in digital and quantitative PCR to support you in ensuring...

The Reagents Behind Much of Molecular Biology

The Reagents Behind Much of Molecular Biology

Thermo Fisher Scientific | 25-Jul-2022 | Case Study

The ability to amplify, modify and fabricate DNA is fundamental to modern molecular biology. Why do so many researchers take their constituent parts for...

Microsampling in Early Phase Drug Development

Microsampling in Early Phase Drug Development

Altasciences | 10-May-2022 | Technical / White Paper

Microsampling significantly lessens the volume of blood and plasma/serum that is collected and analyzed to determine circulating concentrations of therapeutic...

Seasonal Vaccine Manufacturing

Seasonal Vaccine Manufacturing

Baxter BioPharma Solutions | 16-Feb-2022 | Technical / White Paper

The production of seasonal vaccines, such as those for influenza, presents unique challenges to manufacturers due to the necessary time constraints resulting...

Related suppliers

Follow us


View more